Peptide Contraindications: Who Should NOT Use Peptides

Peptide contraindications determine who should not use peptides: some people should avoid them entirely, and others only under specialist oversight. The clearest contraindications are pregnancy and breastfeeding, active or recent cancer, a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 for GLP-1 peptides, and known hypersensitivity. Many research peptides have no human safety data and are not FDA-approved. Always consult your healthcare provider.

Peptide contraindications at a glance

• Absolute (FDA-labeled drugs): personal/family history of MTC or MEN 2 (GLP-1 peptides); active malignancy and acute critical illness (growth-hormone peptides); known hypersensitivity to the peptide or excipients.
• Avoid / specialist-only: pregnancy and breastfeeding; active or recent cancer; children/adolescents (outside approved pediatric indications).
• Use only under close medical supervision: kidney or liver disease, uncontrolled diabetes, active proliferative diabetic retinopathy, cardiovascular disease, and autoimmune conditions.
• Key caveat: most "research peptides" (e.g., BPC-157, TB-500) have no human safety data and are not FDA-approved for any use.
• Bottom line: contraindications are peptide-specific. Screen with a licensed provider before starting anything.

What does "contraindication" mean for peptides?

A contraindication is a specific situation in which a substance should not be used because the risk outweighs any potential benefit. In pharmacology, contraindications are graded: an absolute contraindication means the agent should not be used at all, while a relative contraindication means it may be used only with caution and close monitoring.

"Peptides" is not one thing, so contraindications are peptide-specific. The category spans FDA-approved prescription drugs with rigorously documented labels — such as the GLP-1 receptor agonists semaglutide and tirzepatide, and recombinant growth-hormone products (somatropin) — and a large group of unapproved "research peptides" such as BPC-157 and TB-500, for which human safety data are sparse or absent.

For approved drugs, the contraindications below are taken directly from FDA prescribing information. For research peptides, much of what is known about risk comes from animal and in-vitro studies, plus mechanistic reasoning — which is why "no documented safety data" is itself a reason for caution. Consult your healthcare provider before starting any peptide protocol.

Who should avoid peptides during pregnancy or breastfeeding?

Pregnancy and breastfeeding are among the clearest reasons to avoid most peptides. Peptides act on hormonal, metabolic, and cellular-signaling pathways, and the great majority — including research peptides — have never been studied for safety in pregnant or lactating humans. Absence of data is not evidence of safety.

The FDA-approved GLP-1 peptides make this explicit. The Wegovy (semaglutide) label instructs that, because of the potential for fetal harm, patients should discontinue semaglutide at least 2 months before a planned pregnancy to account for the drug's long half-life, and discontinue it when a pregnancy is recognized; breastfeeding is not recommended during treatment (Wegovy Prescribing Information, FDA 2025). Weight loss offers no benefit during pregnancy and may cause fetal harm.

For unapproved research peptides, no reassuring human pregnancy data exist at all. The conservative, evidence-based position shared across these agents is to avoid use during pregnancy, while trying to conceive, and during breastfeeding. Consult your healthcare provider before using any peptide if you are pregnant, may become pregnant, or are breastfeeding.

Who should avoid peptides if they have cancer?

People with active cancer, or a recent cancer history, are a high-priority group to avoid most growth-promoting and regenerative peptides unless an oncologist explicitly approves. The concern is mechanistic and, for some peptides, supported by laboratory data.

Growth-hormone-axis peptides (such as sermorelin, CJC-1295, ipamorelin, and tesamorelin) raise growth hormone and, downstream, insulin-like growth factor-1 (IGF-1). A large systematic review and meta-regression found that higher circulating IGF-I concentrations are associated with an increased risk of prostate cancer and premenopausal breast cancer, though the associations were modest and varied by site (Renehan et al., 2004, Lancet). For this reason, recombinant growth hormone itself is contraindicated in the presence of active malignancy; any preexisting malignancy should be inactive and its treatment complete before therapy (Genotropin/somatropin Prescribing Information, FDA).

Regenerative peptides raise a separate, theoretical concern. BPC-157 promotes new blood-vessel growth (angiogenesis) through VEGFR2 activation in animal and cell models (Hsieh et al., 2017, J Mol Med). Because tumors depend on angiogenesis to grow, this mechanism prompts caution in people with cancer, even though the effect has not been studied clinically in cancer patients and some 2025 commentary argues BPC-157's effect on angiogenesis is regulatory rather than indiscriminate. Given the uncertainty, anyone with active or recent cancer should consult their oncologist before any peptide. Consult your healthcare provider.

Who is contraindicated for GLP-1 peptides (semaglutide, tirzepatide)?

GLP-1 receptor agonists carry the most specific FDA-labeled contraindications of any widely used peptide drugs. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2), and in patients with a serious hypersensitivity reaction to the drug or its excipients (Ozempic Prescribing Information, FDA; Wegovy Prescribing Information, FDA). This contraindication carries a boxed warning and originates from rodent studies showing thyroid C-cell tumors; the human relevance remains uncertain, but the labeled contraindication stands.

Beyond the absolute contraindications, these peptides require caution in several groups. The labels warn of acute pancreatitis (discontinue if suspected; do not restart if confirmed), and the FDA has required class-wide labeling on the risk of acute kidney injury from dehydration caused by vomiting, diarrhea, and reduced fluid intake (FDA GLP-1 labeling update, 2025). People with a history of pancreatitis, significant kidney disease, gastroparesis, or proliferative diabetic retinopathy should be evaluated individually. Tirzepatide carries the same MTC/MEN 2 contraindication. See our semaglutide guide for detail, and consult your healthcare provider before starting any GLP-1 peptide.

Who is contraindicated for growth-hormone and GH-releasing peptides?

Recombinant growth hormone (somatropin) — and, by mechanistic extension, GH-releasing peptides like sermorelin, CJC-1295, and ipamorelin that raise endogenous GH — has well-defined contraindications in its FDA labeling. Somatropin is contraindicated in:

• Acute critical illness following open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure (associated with increased mortality in trials).
• Active malignancy (any preexisting cancer must be inactive and treatment complete first).
• Active proliferative or severe non-proliferative diabetic retinopathy.
• Prader-Willi syndrome in patients who are severely obese or have a history of upper-airway obstruction, sleep apnea, or severe respiratory impairment (reports of sudden death).
• Known hypersensitivity to somatropin or excipients.

(Genotropin/somatropin Prescribing Information, FDA.)

GH-axis peptides can also worsen insulin resistance and raise blood sugar, so people with uncontrolled diabetes need careful monitoring, and these agents are not appropriate for growth promotion in adolescents with closed growth plates outside approved indications. Because raising the GH/IGF-1 axis is the shared mechanism, the cancer and diabetes cautions above apply to GH-releasing peptides even when used off-label. Consult your healthcare provider.

Who else should avoid or be cautious with peptides?

Several other groups fall into the "avoid or use only under close medical supervision" category, based on organ function, age, and the absence of safety data:

• Children and adolescents. Outside specific FDA-approved pediatric indications (such as somatropin for diagnosed growth-hormone deficiency), peptides should not be used in minors. Growth-plate, hormonal, and developmental effects are not characterized for research peptides.
• Significant kidney or liver disease. These organs clear peptides and their metabolites; impaired function changes exposure and risk. GLP-1 peptides specifically carry a dehydration-related kidney-injury warning (FDA, 2025).
• Known hypersensitivity or prior reaction to a given peptide or its excipients — an absolute contraindication for that agent.
• People taking interacting medications. Peptides that alter blood sugar, blood pressure, or fluid balance can interact with insulin, antihypertensives, and diuretics. Use our peptide interaction checker as a starting point, not a substitute for clinical review.
• Anyone using unverified "research-only" products. Many gray-market peptides are not FDA-approved, may be mislabeled or contaminated, and have no human safety data — a category-level reason for caution regardless of your health status.

Legal status varies by jurisdiction; consult a lawyer for binding advice. Consult your healthcare provider before starting any peptide protocol.

What is the 2026 regulatory status, and why does it matter for safety?

Regulatory status is a practical part of the safety picture, because an unapproved peptide has, by definition, not cleared FDA review for safety and efficacy. In late 2023 the FDA placed BPC-157 and other research peptides on its list of bulk drug substances that "may present significant safety risks" when compounded under section 503A, citing concerns common to peptides — immunogenicity, self-aggregation, and peptide-related impurities (FDA, Certain Bulk Drug Substances That May Present Significant Safety Risks).

The landscape is actively shifting in 2026. Per regulatory trackers, in April 2026 a group of peptides including BPC-157 and TB-500 was moved off the prohibited category pending further review, and the FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to evaluate several peptides for the 503A bulks list, with a public comment period (FDA Advisory Committee Calendar, July 23–24, 2026 PCAC meeting). Separately, compounded semaglutide and tirzepatide became restricted after the FDA declared the national shortage resolved. [VERIFY: exact April 2026 category-change date and the full list of peptides reclassified] Because this is a fast-moving area, confirm the current status of any specific peptide before sourcing it, and see are peptides legal? for the latest. Consult your healthcare provider, and a lawyer for legal questions.

Frequently asked questions

Q: Who should not take peptides? A: The clearest groups to avoid most peptides are people who are pregnant, trying to conceive, or breastfeeding; those with active or recent cancer; and, for GLP-1 peptides specifically, anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Children, people with significant kidney or liver disease, uncontrolled diabetes, or known hypersensitivity should also avoid peptides or use them only under close medical supervision. Many research peptides have no human safety data. Always screen with a licensed healthcare provider first.

Q: Are peptides safe during pregnancy? A: No reassuring human safety data exist for most peptides in pregnancy, so the standard guidance is to avoid them. FDA-approved GLP-1 peptides like semaglutide should be discontinued at least 2 months before a planned pregnancy because of their long half-life and potential for fetal harm (Wegovy Prescribing Information, FDA). Breastfeeding is also not recommended during GLP-1 treatment. For unapproved research peptides, there is no human pregnancy safety data at all. Consult your healthcare provider before using any peptide if you are or may become pregnant.

Q: Can I use peptides if I have cancer or a cancer history? A: This requires oncologist approval, and most growth-promoting peptides are best avoided. Growth-hormone-axis peptides raise IGF-1, which is associated with increased risk of certain cancers (Renehan et al., 2004, Lancet), and recombinant growth hormone is contraindicated in active malignancy. Regenerative peptides like BPC-157 promote angiogenesis in animal models (Hsieh et al., 2017, J Mol Med), a theoretical concern given tumors' reliance on blood-vessel growth. If you have active or recent cancer, discuss any peptide with your oncologist before use.

Q: Why are semaglutide and tirzepatide contraindicated in thyroid cancer? A: Both carry a boxed warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 (Ozempic and Wegovy Prescribing Information, FDA). The warning comes from rodent studies showing thyroid C-cell tumors at clinically relevant exposures. Whether this translates to human risk remains uncertain, but the labeled contraindication is in force. If you have a thyroid nodule or a family history of MTC/MEN 2, tell your provider before considering a GLP-1 peptide.

Q: Can children or teenagers use peptides? A: Generally no, outside specific FDA-approved pediatric indications such as somatropin for diagnosed growth-hormone deficiency under specialist care. Research peptides have not been studied for safety in minors, and they can affect growth plates, hormones, and development. Somatropin itself should not be used for growth promotion once growth plates have closed. Any consideration of peptides in a minor must go through a pediatric specialist.

Q: Do peptides interact with other medications? A: They can. Peptides that affect blood sugar (GLP-1 agonists, GH-releasing peptides), blood pressure, or fluid balance may interact with insulin, antihypertensives, and diuretics, and GLP-1 peptides slow gastric emptying, which can alter absorption of oral medications. The FDA has required kidney-injury warnings on GLP-1 drugs related to dehydration. Review your full medication list — including supplements — with a pharmacist or physician, and use our interaction checker as a screening starting point, not a final answer.

Q: Are unapproved "research" peptides safe to use? A: They carry added risk precisely because they are unapproved. Products like BPC-157 and TB-500 are not FDA-approved for any use, lack human safety data, and the FDA has flagged peptide bulk substances for risks including immunogenicity and impurities (FDA, Certain Bulk Drug Substances That May Present Significant Safety Risks). Gray-market products may also be mislabeled or contaminated. This is a category-level reason for caution regardless of your individual health status. Consult your healthcare provider before using any peptide.

References

1. Hsieh MJ, Lee CH, Chueh HY, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966. https://pubmed.ncbi.nlm.nih.gov/27847966/
2. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. PMID: 15110491. https://pubmed.ncbi.nlm.nih.gov/15110491/
3. U.S. Food & Drug Administration. OZEMPIC (semaglutide) injection — Highlights of Prescribing Information (Contraindications: MTC, MEN 2, hypersensitivity; pancreatitis warning). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
4. U.S. Food & Drug Administration. WEGOVY (semaglutide) injection — Highlights of Prescribing Information (Contraindications; discontinue ≥2 months before planned pregnancy; breastfeeding not recommended). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
5. U.S. Food & Drug Administration / Pfizer. GENOTROPIN (somatropin) — Prescribing Information / Contraindications (acute critical illness, active malignancy, diabetic retinopathy, Prader-Willi syndrome, hypersensitivity). https://www.pfizermedical.com/genotropin/contradictions
6. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (peptide immunogenicity, impurities; 503A category). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
7. U.S. Food & Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026